A study published in Nature Medicine in July 2026 has provided new insights into the genetic basis of fibromyalgia, a condition that affects 2 to 4 percent of the population, mostly women. Characterized by widespread, persistent pain and heightened sensitivity to touch, fibromyalgia is considered a nociplastic pain condition—meaning the pain arises from the nervous system's processing of signals, not from visible tissue damage or neurological injury. Michael Wainberg, a researcher at the Lunenfeld-Tanenbaum Research Institute and co-author of the study, emphasized that the findings add to the growing evidence that fibromyalgia is a legitimate medical condition. The study analyzed the genomes of over 2 million people, including nearly 55,000 with fibromyalgia, and identified 26 genetic loci—specific regions on chromosomes—linked to the risk of developing the condition. While these loci overlap with those of other diseases, they offer the strongest evidence to date of a genetic predisposition specific to fibromyalgia. One of the study’s surprising findings is that no genetic differences were found between men and women, despite the condition being far more common in women. Nasa Sinnott-Armstrong, a computational biologist and co-author, explained that this could mean either the same biological mechanisms are at play but expressed differently due to hormonal influences, or that men and women develop the disease through distinct pathways influenced by external factors such as lifestyle or environment. Wainberg suggested that non-genetic factors, such as hormonal differences or underdiagnosis in men, might explain the gender gap in fibromyalgia prevalence. The research also uncovered a gene variant strongly associated with fibromyalgia risk: a part of the HTT gene, which is linked to Huntington’s disease. While this connection was unexpected, the variant is located in a completely different region of the gene than the one responsible for Huntington’s disease. This finding could be significant because it suggests that drugs tested for Huntington’s disease might also be useful for fibromyalgia. The study also highlights other genes involved in pain regulation and neurological function, such as GPR52, a receptor gene linked to experimental chronic pain treatments, and a dopamine-related gene involved in psychiatric disorders. These findings reinforce the idea that fibromyalgia is primarily a nervous system disease. The study also identified strong genetic signals in brain tissues and neuronal cells, including neurons in the dentate gyrus of the hippocampus, a brain region involved in memory and sensory processing. This could help explain the "fibro fog"—cognitive difficulties experienced by many patients. Another significant finding was the association with enteric neurons in the digestive system, which may explain the link between fibromyalgia and irritable bowel syndrome, suggesting the role of the gut-brain axis in the condition. However, researchers caution that genetic signatures of similar cell types often overlap, so further studies are needed. The study’s findings do not fully explain the heritability of fibromyalgia, which appears to be concentrated in the brain rather than in immune cells. This challenges the idea of fibromyalgia being primarily an autoimmune disease, as no significant immune-related genetic signals were found. Sinnott-Armstrong noted that while the immune system might still play a role, the condition’s genetic basis is mainly defined by neurons. The research provides important clues about the development of fibromyalgia and potential therapeutic targets, but it does not offer a way to predict individual risk or a definitive diagnostic test. Wainberg concluded that while repurposing existing drugs for fibromyalgia is promising, turning these discoveries into approved treatments remains a complex challenge.